Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Plus Cisplatin vs Etoposide Plus Cisplatin in Extensive Stage Small-Cell Lung Cancer
NCT02348450Phase 4Unknown
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Feb 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of irinotecan in small cell lung cancer (SCLC) (2 arms), sponsored by Guangdong Association of Clinical Trials. Primary endpoint: Progression Free Survival at 24 months. Status: unknown.
02
Drugs
irinotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02348450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348450.